The Library
Non-invasive respiratory support strategies in COVID-19
Tools
Gorman, Ellen, Connolly, Bronwen, Couper, Keith, Perkins, Gavin D. and McAuley, Daniel F. (2021) Non-invasive respiratory support strategies in COVID-19. The Lancet Respiratory Medicine, 9 (6). pp. 553-556. doi:10.1016/S2213-2600(21)00168-5
|
PDF
WRAP-non-invasive-respiratory-support-strategies-COVID-19-Couper-2021.pdf - Accepted Version - Requires a PDF viewer. Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (1332Kb) | Preview |
Official URL: http://dx.doi.org/10.1016/S2213-2600(21)00168-5
Abstract
In hospitalised patients with COVID-19, an increase in oxygen requirements prompts the clinician to decide how and when to escalate treatment. A key treatment goal is to avoid, where possible, the need for invasive mechanical ventilation. However, up to 20% of hospitalised patients in the UK require admission to critical care units, and around 40% of those requiring invasive mechanical ventilation for COVID-19 pneumonitis do not survive.1 To date, the only treatments that have been shown to reduce the need for invasive mechanical ventilation are dexamethasone and interleukin-6 blockade.
Non-invasive respiratory support strategies, such as continuous positive airway pressure (CPAP) or high-flow nasal oxygen (HFNO), are attractive treatment options that might avoid the need for invasive mechanical ventilation and its inherent risks. In the context of COVID-19, concern has been raised that these strategies might cause harm to patients through delays to tracheal intubation or exacerbation of lung injury, to health-care workers through nosocomial infection, and to health-care systems through the high oxygen demand of devices.
Item Type: | Journal Item | ||||||||
---|---|---|---|---|---|---|---|---|---|
Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||
Library of Congress Subject Headings (LCSH): | COVID-19 (Disease), COVID-19 (Disease) -- Patients -- Treatment , Oxygen therapy, Respiratory therapy | ||||||||
Journal or Publication Title: | The Lancet Respiratory Medicine | ||||||||
Publisher: | The Lancet Publishing Group | ||||||||
ISSN: | 2213-2600 | ||||||||
Official Date: | 1 June 2021 | ||||||||
Dates: |
|
||||||||
Volume: | 9 | ||||||||
Number: | 6 | ||||||||
Page Range: | pp. 553-556 | ||||||||
DOI: | 10.1016/S2213-2600(21)00168-5 | ||||||||
Status: | Peer Reviewed | ||||||||
Publication Status: | Published | ||||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||||
Date of first compliant deposit: | 17 May 2021 | ||||||||
Date of first compliant Open Access: | 16 October 2021 |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |
Downloads
Downloads per month over past year